The Brii Biosciences-backed lung disease treatment developer priced an upsized offering in the middle of its range.

US-based lung disease therapy developer AN2 Therapeutics, which counts pharmaceutical firm Brii Biosciences as a backer, has raised $69m in an initial public offering on the Nasdaq Global Select Market. The offering involved the sale of 4.6 million shares, upsized from 4 million and priced at $15.00 each, in the middle of the offering’s $14…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.